The role of the inflammatory microenvironment in thyroid carcinogenesis

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages

  Cunha, Lucas Leite ^a   Marcello, Marjory Alana ^a   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Inflammatory microenvironment; Thyroid carcinomas; Tumor associated macrophages; Tumor infiltrating lymphocytes

Indexed keywords

CHEMOKINE; CYTOKINE;

ADVANCED CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POORLY DIFFERENTIATED THYROID CANCER; RECURRENCE RISK; REVIEW; THYROID CANCER; THYROID CARCINOGENESIS; THYROID CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; IMMUNOLOGY; PATHOLOGY; THYROID TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; THYROID NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84903592057     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0431     Document Type: Review

References (178)

1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK & Sethi G 2006 Inflammation and cancer: how hot is the link? Biochemical Pharmacology 72 1605-1621. (doi:10.1016/j.bcp.2006.06.029) (Pubitemid 44666739)
2. Ahmed OI, Adel AM, Diab DR & Gobran NS 2006 Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egyptian Journal of Immunology 13 61-68.
3. Akdis M 2011 Interleukins, from 1 to 37, and interferon-g: receptors, functions, and roles in diseases (vol 127, pg 701, 2011). Journal of Allergy and Clinical Immunology 128 739. (doi:10.1016/j.jaci.2011.07.022)
4. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O et al. 2011 Interleukins, from 1 to 37, and interferon-g: receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology 127 701-717. (doi:10.1016/j.jaci.2010.11.050)
5. Amino N, Pysher T, Cohen EP & Degroot LJ 1975 Immunologic aspects of human thyroid cancer. Humoral and cell-mediated immunity, and a trial of immunotherapy. Cancer 36 963-973. (doi:10.1002/1097-0142(197509)36:3〈963:: AID-CNCR2820360319〉3.0.CO;2-3)
6. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M,Carmi Y, Dvorkin T, White RM, Gayvoronsky L et al. 2006 Effects of micro-environmentand malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. European Journal of Cancer 42 751-759. (doi:10.1016/j.ejca.2006.01.010)
7. Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS et al. 2003 Transient activation of NF-κB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 22 412-425. (doi:10.1038/sj.onc.1206132) (Pubitemid 36194337)
8. Bach EA, Aguet M & Schreiber RD 1997 The IFNγ receptor: a paradigm for cytokine receptor signaling. Annual Review of Immunology 15 563. (doi:10.1146/annurev.immunol.15.1.563)
9. Balkwill F & Mantovani A 2001 Inflammation and cancer: back to Virchow? Lancet 357 539-545. (Pubitemid 32173595)
10. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B & Palucka K 2000 Immunobiology of dendritic cells. Annual Review of Immunology 18 767-811. (doi:10.1146/annurev.immunol.18.1.767) (Pubitemid 30365397)
11. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW & Ritz J 1992 Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. European Journal of Immunology 22 1-6. (doi:10.1002/eji.1830220102)
12. Baur A, Bauer K, Jarry H & Kohrle J 2000 Effects of proinflammatory cytokines on anterior pituitary 5′-deiodinase type I and type II. Journal of Endocrinology 167 505-515. (doi:10.1677/joe.0.1670505) (Pubitemid 32047558)
13. Benomar Y, Gertler A, De Lacy P, Crepin D, Hamouda HO, Riffault L & Taouis M 2013 Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 62 102-114. (doi:10.2337/db12-0237)
14. Beumer W, Effraimidis G, Drexhage RC, Wiersinga WM & Drexhage HA 2013 Changes in serum adhesion molecules, chemokines, cytokines, and tissue remodeling factors in euthyroid women without thyroid antibodies who are at risk for autoimmune thyroid disease: a hypothesis on the early phases of the endocrine autoimmune reaction. Journal of Clinical Endocrinology and Metabolism 98 2460-2468. (doi:10.1210/jc.2012-4122)
15. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R & Cerami A 1985 Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316 552-554. (doi:10.1038/316552a0) (Pubitemid 16239366)
16. Bhatti I, Peacock O, Lloyd G, Larvin M & Hall RI 2010 Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. American Journal of Surgery 200 197-203. (doi:10.1016/j.amjsurg.2009.08.041)
17. Bierie B & Moses HL 2006 Tumour microenvironment: TGFb: the molecular Jekyll and Hyde of cancer. Nature Reviews. Cancer 6 506-520. (doi:10.1038/nrc1926) (Pubitemid 43980540)
18. Bokarewa M, Nagaev I, Dahlberg L, Smith U & Tarkowski A 2005 Resistin, an adipokine with potent proinflammatory properties. Journal of Immunology 174 5789-5795. (Pubitemid 40593223)
19. Brown TJ, Lioubin MN & Marquardt H 1987 Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor β1, interferon-γ, and oncostatin M for human melanoma cells. Journal of Immunology 139 2977-2983. (Pubitemid 17157467)
20. Bruland O, Fluge O, Akslen LA, Eiken HG, Lillehaug JR, Varhaug JE & Knappskog PM 2009 Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer 9 425. (doi:10.1186/1471-2407-9-425)
21. Bufalo NE, Leite JL, Guilhen AC, Morari EC, Granja F, Assumpcao LV & Ward LS 2006 Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants. Endocrine-Related Cancer 13 1185-1193. (doi:10.1677/ERC-06-0002) (Pubitemid 46212572)
22. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M & Dupuy C 2011 Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS ONE 6 e22567. (doi:10.1371/journal.pone.0022567)
23. Caturegli P, Hejazi M, Suzuki K, Dohan O, Carrasco N, Kohn LD & Rose NR 2000 Hypothyroidism in transgenic mice expressing IFN-g in the thyroid. PNAS 97 1719-1724. (doi:10.1073/pnas.020522597) (Pubitemid 30118509)
24. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T & Bowness P 2007 CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. Journal of Immunology 179 89-94. (Pubitemid 46986521)
25. Chen BH, Song Y, Ding EL, Manson JE, Roberts CK, Rifai N, Buring JE, Gaziano JM & Liu S 2010 Association of resistin promoter polymorphisms with plasma resistin levels and type 2 diabetes in women and men. International Journal of Molecular Epidemiology and Genetics 1 167-174.
26. Chen CJ, Sung WW, Su TC, Chen MK, Wu PR, Yeh KT, Ko JL & Lee H 2013 High expression of interleukin 10might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clinica Chimica Acta 415 25-30. (doi:10.1016/j.cca.2012.09.009)
27. Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP & Liu CL 2010 Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 147 847-853. (doi:10.1016/j.surg.2009.11. 004)
28. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H et al. 2012 Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61 427-438. (doi:10.1136/gutjnl-2011-300509)
29. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, Chiang JM & Lin JR 2012 Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? International Journal of Colorectal Disease 27 1347-1357. (doi:10.1007/s00384- 012-1459-x)
30. Chow KC, Chiou SH, Ho SP, Tsai MH, Chen CL, Wang LS & Chi KH 2003 The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncology Reports 10 813-819.
31. Clement JM & McDermott DF 2009 The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer 7 E7-E9. (doi:10.3816/CGC.2009.n. 014)
32. Cooper MA, Fehniger TA & Caligiuri MA 2001a The biology of human natural killer-cell subsets. Trends in Immunology 22 633-640. (doi:10.1016/S1471-4906(01)02060-9) (Pubitemid 33043908)
33. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE & Caligiuri MA 2001b Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 3146-3151. (doi:10.1182/blood.V97.10.3146)
34. Cowin AJ & Bidey SP 1995 Porcine thyroid follicular cells in monolayer culture activate the iodide-responsive precursor form of transforming growth factor-β1. Journal of Endocrinology 144 67-73. (doi:10.1677/joe.0. 1440067)
35. Cronan JJ 2008 Thyroid nodules: is it time to turn off the US machines? Radiology 247 602-604. (doi:10.1148/radiol.2473072233)
36. Cunha LL & Ward LS 2011 Comments on "well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence". Endocrine Pathology 22 172-173. (doi:10.1007/s12022-011-9171-x)
37. Cunha LL & Ward LS 2012 Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. European Archives of Oto-Rhino-Laryngology 269 699-700. (doi:10.1007/s00405-011-1764-y)
38. Cunha LL, Tincani AJ, da Assumpcao LV, Soares FA, Vassallo J & Ward LS 2011 Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics 66 1203-1208. (doi:10.1590/S1807-59322011000700014)
39. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J & Ward LS 2012a Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. Endocrine-Related Cancer 19 L31-L36. (doi:10.1530/ERC-11-0285)
40. Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, Soares FA, Vassallo J & Ward LS 2012b Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clinical Endocrinology 77 918-925. (doi:10.1111/j.1365-2265.2012.04482.x)
41. Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J & Ward LS 2013 Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocrine-Related Cancer 20 103-110. (doi:10.1530/ERC-12-0313)
42. Davis PJ 2008 Cytokines and growth factors and thyroid hormone. Current Opinion in Endocrinology, Diabetes, and Obesity 15 428.
43. Davoine F, SimA, TangC, Fisher S, EthierC, Puttagunta L,Wu Y,McGawWT, Yu D, Cameron L et al. 2013 Eosinophils in human oral squamous carcinoma; role of prostaglandin D2. Journal of Inflammation 10 4. (doi:10.1186/1476-9255-10-4)
44. Dranoff G 2004 Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews. Cancer 4 11-22. (doi:10.1038/nrc1252) (Pubitemid 38111131)
45. Dunn GP, Bruce AT, Ikeda H, Old LJ & Schreiber RD 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 3 991-998. (doi:10.1038/ni1102-991) (Pubitemid 35363648)
46. Egler RA, Burlingame SM, Nuchtern JG & Russell HV 2008 Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clinical Cancer Research 14 7028-7034. (doi:10.1158/1078-0432.CCR-07-5017)
47. Eke Koyuncu C, Turkmen Yildirmak S, Temizel M, Ozpacaci T, Gunel P, Cakmak M & Ozbanazi YG 2013 Serum resistin and insulin-like growth factor-1 levels in patients with hypothyroidism and hyperthyroidism. Journal of Thyroid Research 2013 306750. (doi:10.1155/2013/306750)
48. El Demellawy D, Nasr A & Alowami S 2008 Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagnostic Pathology 3 5. (doi:10.1186/1746-1596-3-5)
49. Eloy C, Santos J, Cameselle-Teijeiro J, Soares P & Sobrinho-Simoes M 2012 TGF-β/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Archiv 460 587-600. (doi:10.1007/s00428-012-1234-y)
50. Fabregat I, Fernando J, Mainez J & Sancho P 2013 TGF-β signaling in cancer treatment. Current Pharmaceutical Design [in press].
51. Fan J, Nishanian P, Breen EC, McDonald M& Fahey JL 1998 Cytokine gene expression in normal human lymphocytes in response to stimulation. Clinical and Diagnostic Laboratory Immunology 5 335-340. (Pubitemid 28246456)
52. Fiumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R & Gangemi P 1997 In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 82 1615-1620. (doi:10.1210/jc.82.5.1615) (Pubitemid 27200444)
53. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP & Haugen BR 2010 Tumor-associated lymphocytes and increased FoxP3 + regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2325-2333. (doi:10.1210/jc.2009-2564)
54. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP & Haugen BR 2012 Programmed death-1+T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 97 E934-E943. (doi:10.1210/jc.2011-3428)
55. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK & Caligiuri MA 2006 Evidence for discrete stages of human natural killer cell differentiation in vivo. Journal of Experimental Medicine 203 1033-1043. (doi:10.1084/jem.20052507)
56. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS & Albelda SM 2009 Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16 183-194. (doi:10.1016/j.ccr.2009.06.017)
57. Gillespie EF, Raychaudhuri N, Papageorgiou KI, Atkins SJ, Lu Y, Charara LK, Mester T, Smith TJ & Douglas RS 2012 Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB. Investigative Ophthalmology & Visual Science 53 7746-7753. (doi:10.1167/iovs.12-9861)
58. Gogali F, Paterakis G, Rassidakis GZ, Kaltsas G, Liakou CI, Gousis P, Neonakis E, Manoussakis MN & Liapi C 2012 Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid. Journal of Clinical Endocrinology and Metabolism 97 1474-1482. (doi:10.1210/jc.2011-1838)
59. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV & Ward LS 2004a GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Letters 209 129-137. (doi:10.1016/j.canlet.2003.12.013)
60. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV & Ward LS 2004b Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Letters 210 151-157. (doi:10.1016/j.canlet.2004.01.016) (Pubitemid 38748685)
61. Guilhen AC, Bufalo NE, Morari EC, Leite JL, Assumpcao LV, Tincani AJ & Ward LS 2009 Role of the N-acetyltransferase 2 detoxification system in thyroid cancer susceptibility. Clinical Cancer Research 15 406-412. (doi:10.1158/1078-0432.CCR-08-1835)
62. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R & Francis GL 2001 Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. Journal of Clinical Endocrinology and Metabolism 86 1346-1354. (doi:10.1210/jc.86.3.1346) (Pubitemid 32323027)
63. Halama N, Zoernig I & Jaeger D 2010 Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. Journal of Oncology 2010 689893. (doi:10.1155/2010/689893)
64. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N et al. 2007 Programmed cell death 1 ligand 1 and tumor-infiltrating CD8C T lymphocytes are prognostic factors of human ovarian cancer. PNAS 104 3360-3365. (doi:10.1073/pnas.0611533104) (Pubitemid 46364164)
65. Han JM, Kim TY, Jeon MJ,Yim JH, Kim WG, Song DE, Hong SJ, Bae SJ, Kim HK, Shin MH et al. 2013 Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. European Journal of Endocrinology 168 879-886. (doi:10.1530/EJE-13-0065)
66. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
67. Hardy CL & Balducci L 1985 Hemopoietic alterations of cancer. American Journal of the Medical Sciences 290 196-205. (doi:10.1097/00000441- 198511000-00004)
68. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, Usadel KH & Hubner K 1994 T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. Journal of Cancer Research and Clinical Oncology 120 651-656. (doi:10.1007/BF01245376)
69. Hilly O, Koren R, Raz R, Rath-Wolfson L, Mizrachi A, Hamzany Y, Bachar G & Shpitzer T 2013 The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma. American Journal of Clinical Pathology 139 87-92. (doi:10.1309/AJCPAKYDO56NKMYZ)
70. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH & Kishimoto T 1985 Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). PNAS 82 5490-5494. (doi:10.1073/pnas.82.16.5490) (Pubitemid 15012129)
71. Hirashima M, Higuchi S, Sakamoto K, Nishiyama T & Okada H 1998 The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. Journal of Cancer Research and Clinical Oncology 124 329-334. (doi:10.1007/s004320050178) (Pubitemid 28332916)
72. Hoon DS, Banez M, Okun E, Morton DL & Irie RF 1991 Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Research 51 2002-2008.
73. van Horssen R, ten Hagen TL & Eggermont AM 2006 TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11 397-408. (doi:10.1634/theoncologist.11-4-397)
74. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T & Paul WE 1982 Identification of a T cell-derived b cell growth factor distinct from interleukin 2. Journal of ExperimentalMedicine 155 914-923. (doi:10.1084/jem.155.3.914) (Pubitemid 12187863)
75. Hsia CY, Huo TI, Chiang SY, Lu MF, Wu JC, Lui WY, Lee SD & Wu CW 2006 Evaluation of interleukin-6, interleukin-10, and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 21 A187-A187.
76. Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA & Febbo PG 2010 Immune signatures predict prognosis in localized cancer. Cancer Investigation 28 765-773. (doi:10.3109/ 07357900903095755)
77. Huang BY, Hseuh C, Chao TC, Lin KJ & Lin JD 2011 Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocrine Pathology 22 144-149. (doi:10.1007/s12022-011-9164-9)
78. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N & Jones SA 2001 IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14 705-714. (doi:10.1016/S1074-7613(01) 00151-0) (Pubitemid 32592418)
79. Ikeguchi M, Hatada T, Yamamoto M,Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H & Tatebe S 2009 Serum interleukin-6 and-10 levels in patients with gastric cancer. Gastric Cancer 12 95-100. (doi:10.1007/s10120-009-0509-8)
80. Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, Rebai A, Glasson E, Abid M, Ayadi F et al. 2012 IL-1b a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. European Cytokine Network 23 101-106.
81. Kang JH, Yu BY & Youn DS 2007 Relationship of serum adiponectin and resistin levels with breast cancer risk. Journal of KoreanMedical Science 22 117-121. (doi:10.3346/jkms.2007.22.1.117)
82. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M,Old LJ&Schreiber RD 1998 Demonstration of an interferon g-dependent tumor surveillance system in immunocompetent mice. PNAS 95 7556-7561. (doi:10.1073/pnas.95.13.7556) (Pubitemid 28293291)
83. Karre K, Ljunggren HG, Piontek G & Kiessling R 1986 Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 675-678. (doi:10.1038/319675a0) (Pubitemid 16119452)
84. Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, Kim MK, Kim W & Myung SC 2011 Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU International 108 E77-E83. (doi:10.1111/j.1464-410X.2010.09813.x)
85. Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RM & Studer H 1999 Expression of transforming growth factor β(1), β (2), and β (3) in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 9 119-125. (doi:10.1089/thy.1999.9.119) (Pubitemid 29115531)
86. Kimura H, Kimura M, Westra WH, Rose NR & Caturegli P 2005 Increased thyroidal fat and goitrous hypothyroidism induced by interferon-γ. International Journal of Experimental Pathology 86 97-106. (doi:10.1111/j.0959- 9673.2005.00418.x) (Pubitemid 40523810)
87. Kimura HJ, Chen CY, Tzou SC, Rocchi R, Landek-Salgado MA, Suzuki K, Kimura M, Rose NR & Caturegli P 2009 Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice. PLoS ONE 4 e7857. (doi:10.1371/journal.pone.0007857)
88. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P & Ferrone S 2012 Immunotherapy of cancer in 2012. CA: A Cancer Journal for Clinicians 62 309-335. (doi:10.3322/caac.20132)
89. Kloke O, Wandl U, Opalka B,Moritz T, Nagel-HiemkeM, Franz T, Becher R, Hirche H, Seeber S & Niederle N 1992 A prospective randomized comparison of single-agent interferon (IFN)-α with the combination of IFN-α and low-dose IFN-γ in chronic myelogenous leukaemia. European Journal of Haematology 48 93-98.
90. KumadaM, Kihara S,Ouchi N, KobayashiH, Okamoto Y, Ohashi K,Maeda K, Nagaretani H, Kishida K, Maeda N et al. 2004 Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 2046-2049. (doi:10.1161/01.CIR.0000127953. 98131.ED) (Pubitemid 38620209)
91. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM & Gutterman JU 1987 Therapy of chronic myelogenous leukemia with recombinant interferon-g. Blood 70 943-947. (Pubitemid 18022365)
92. Kwon H & Pessin JE 2013 Adipokines mediate inflammation and insulin resistance. Frontiers in Endocrinology 4 71. (doi:10.3389/fendo.2013.00071)
93. Lanier LL 2008 Up on the tightrope: natural killer cell activation and inhibition. Nature Immunology 9 495-502. (doi:10.1038/ni1581) (Pubitemid 351560518)
94. Lanier LL, Le AM, Civin CI, Loken MR & Phillips JH 1986 The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. Journal of Immunology 136 4480-4486. (Pubitemid 16090665)
95. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S & Evers BM 2007 Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. Journal of the American College of Surgeons 204 764-773 (discussion 773-775). (doi:10.1016/j.jamcollsurg.2006.12.037)
96. Lee DH 2012 Morphologic evidence of anti-tumor specificity of T cells activated by dendritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients. Korean Journal of Physiology & Pharmacology 16 243-247. (doi:10.4196/kjpp.2012.16.4.243)
97. Lewis JD, Reilly BD & Bright RK 2003 Tumor-associated antigens: from discovery to immunity. International Reviews of Immunology 22 81-112. (doi:10.1080/08830180305221) (Pubitemid 36758540)
98. Lewis AM, Varghese S, Xu H & Alexander HR 2006 Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. Journal of Translational Medicine 4 48. (doi:10.1186/1479-5876-4-48)
99. Li S, Shin HJ, Ding EL & van Dam RM 2009 Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. Journal of the American Medical Association 302 179-188. (doi:10.1001/jama.2009.976)
100. Liang X, De Vera ME, Buchser WJ, Romo de Vivar Chavez A, Loughran P, Beer Stolz D, Basse P, Wang T, Van Houten B, Zeh HJ III et al. 2012 Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Research 72 2791-2801. (doi:10.1158/0008-5472.CAN-12-0320)
101. Liapi C, Gogali F, Paterakis G, Rassidakis GZ & Liakou CI 2013 CD3-CD16-CD56 bright immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid (epub).
102. Lin Q, Huang MS, Hu B, Dong M, Wen JY & Wu XY 2007 Serum levels of macrophage migration inhibitory factor and interleukin-8 in hepatocellular carcinoma patients: their correlations with tumor progression and prognosis. Zhonghua Gan Zang Bing Za Zhi 15 463-464.
103. Liotti F, Visciano C & Melillo RM 2012 Inflammation in thyroid oncogenesis. American Journal of Cancer Research 2 286-297.
104. Lippitz BE 2013 Cytokine patterns in patients with cancer: a systematic review. Lancet Oncology 14 e218-e228. (doi:10.1016/S1470-2045(12)70582-X)
105. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC & Cheng SP 2013 Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. Journal of Surgical Oncology 107 493-497. (doi:10.1002/jso.23270)
106. Ljunggren HG 2008 Cancer immunosurveillance: NKG2D breaks cover. Immunity 28 492-494. (doi:10.1016/j.immuni.2008.03.007)
107. Mantovani A, Sozzani S, Locati M, Allavena P & Sica A 2002 Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 23 549-555. (doi:10.1016/S1471- 4906(02)02302-5) (Pubitemid 35223554)
108. Marcello MA, Sampaio AC, Geloneze B, Vasques AC, Assumpcao LV & Ward LS 2012 Obesity and excess protein and carbohydrate consumption are risk factors for thyroid cancer. Nutrition and Cancer 64 1190-1195. (doi:10.1080/01635581. 2012.721154)
109. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K & Tamai H 1995 The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. Journal of Clinical Endocrinology and Metabolism 80 3421-3424. (doi:10.1210/jc.80.12.3421) (Pubitemid 3019478)
110. Mazzaferri EL 2006 Managing small thyroid cancers. Journal of the American Medical Association 295 2179-2182. (doi:10.1001/jama.295.18.2179)
111. Medzhitov R 2010 Inflammation 2010: new adventures of an old flame. Cell 140 771-776. (doi:10.1016/j.cell.2010.03.006)
112. Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A et al. 2010 Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 29 6203-6215. (doi:10.1038/onc.2010.348)
113. Miller CHT, Maher SG & Young HA 2009 Clinical use of interferon-g. Annals of the New York Academy of Sciences 1182 69-79. (doi:10.1111/j.1749-6632. 2009.05069.x)
114. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, Kyttaris V, Panagiotou V, Mylvaganam G et al. 2011 Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 96 E2023-E2028. (doi:10.1210/jc.2010-1908)
115. Modi J, Patel A, Terrell R, Tuttle RM & Francis GL 2003 Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. Journal of Clinical Endocrinology and Metabolism 88 4418-4425. (doi:10.1210/jc.2003-030342) (Pubitemid 37153752)
116. Morari EC, Silva JR, Guilhen AC, Cunha LL, Marcello MA, Soares FA, Vassallo J & Ward LS 2010 Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome. Endocrine Pathology 21 242-249. (doi:10.1007/s12022-010-9137-4)
117. Morosini PP, Taccaliti A, Arnaldi G, Simonella G, Petrelli MD, Mancini V, Montironi R, Scarpelli M, Diamanti L & Mantero F 1996 Enhanced expression of transforming growth factor b1 in rat thyroid hyperplasia is thyrotropin induced and time dependent. European Journal of Endocrinology 134 373-378. (doi:10.1530/eje.0.1340373) (Pubitemid 26108156)
118. Murphy K 2011 Innate Immunity. In K Murphy (Ed.) Janeway's Immunobiology, edn 8, 37-73. New York: Garland Science.
119. Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG & Fugazzola L 2010 The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clinical Endocrinology 72 702-708. (doi:10.1111/j.1365-2265.2009.03699.x)
120. Nagumo A, Yasuda K, Numazaki H, Azuma H, Tanabe Y, Kikuchi S, Harata S & Tohyama H 2005 Effects of separate application of three growth factors (TGF-β1, EGF, and PDGF-BB) on mechanical properties of the in situ frozen-thawed anterior cruciate ligament. Clinical Biomechanics 20 283-290. (doi:10.1016/j.clinbiomech.2004.11.004) (Pubitemid 40247683)
121. Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M & Hirano M 2002 Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. European Journal of Haematology 68 91-100. (doi:10.1034/j.1600-0609.2002.01609. x) (Pubitemid 34478273)
122. NikiforovYE 2010 Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer 116 1626-1628. (doi:10.1002/cncr.24889)
123. Nikiteas NI, Tzanakis N,Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A & Peros G 2005 Serum IL-6, TNF-α and CRP levels in Greek colorectal cancer patients: prognostic implications. World Journal of Gastroenterology 11 1639-1643. (Pubitemid 40520804)
124. Onishi T, Ohishi Y, Imagawa K, Ohmoto Y & Murata K 1999 An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. BJU International 83 488-492. (doi:10.1046/j.1464-410x. 1999.00925.x) (Pubitemid 29151178)
125. Ouyang Q, Baerlocher G, Vulto I & Lansdorp PM 2007 Telomere length in human natural killer cell subsets. Annals of the New York Academy of Sciences 1106 240-252. (doi:10.1196/annals.1392.001) (Pubitemid 47443037)
126. Park SW, Kim MK, Kwon KH & Kim J 2012 Association between a promoter polymorphism (rs2192752,-1028A/C) of interleukin 1 receptor, type I (IL1R1) and location of papillary thyroid carcinoma in a Korean population. International Journal of Immunogenetics 39 501-507. (doi:10.1111/j.1744-313X.2012.01125.x)
127. Perrier S, Caldefie-Chezet F & Vasson MP 2009 IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Letters 583 259-265. (doi:10.1016/j.febslet.2008.12.030)
128. Popova EV, Popova NP, Aliab'eva IV & Gatiatulina ER 2012 Interleukin-6 in endemic goiter patients in the southUral region. Gigiena i Sanitariia 9-10.
129. Poschke I, Mougiakakos D & Kiessling R 2011 Camouflage and sabotage: tumor escape from the immune system. Cancer Immunology, Immunotherapy 60 1161-1171. (doi:10.1007/s00262-011-1012-8)
130. Proietti A, Ugolini C, Melillo RM, Crisman G, Elisei R, SantoroM,MinutoM, VittiP,Miccoli P&Basolo F 2011Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 21 1209-1215. (doi:10.1089/thy.2011.0059)
131. Pusztaszeri MP, Sadow PM & FaquinWC 2013 Association of CD1α-positive dendritic cells with papillary thyroid carcinoma in thyroid fine-needle aspirations: a cytologic and immunocytochemical evaluation. Cancer Cytopathology 121 206-213. (doi:10.1002/cncy.21239)
132. Rebuffat SA, Kammoun-Krichen M, Charfeddine I, Ayadi H, Bougacha-Elleuch N & Peraldi-Roux S 2013 IL-1b and TSH disturb thyroid epithelium integrity in autoimmune thyroid diseases. Immunobiology 218 285-291. (doi:10.1016/j.imbio. 2012.05.016)
133. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L & Dammacco F 2001 The role of mast cells in tumour angiogenesis. British Journal of Haematology 115 514-521. (doi:10.1046/j.1365-2141.2001.03202.x) (Pubitemid 34015640)
134. Roberts AB & Wakefield LM 2003 The two faces of transforming growth factor b in carcinogenesis. PNAS 100 8621-8623. (doi:10.1073/pnas.1633291100) (Pubitemid 36899145)
135. Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, Leporati P, La Manna L, Magri F, Mariotti S& Chiovato L 2013 Interferon-γ and tumor necrosis factor-a sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? Journal of Clinical Endocrinology and Metabolism 98 308-313. (doi:10.1210/jc.2012-2555)
136. Ruco LP, Ranalli T, Marzullo A, Bianco P, Prat M, Comoglio PM & Baroni CD 1996 Expression of Met protein in thyroid tumours. Journal of Pathology 180 266-270. (doi:10.1002/(SICI)1096-9896(199611)180:3〈266:: AIDPATH658〈.0.CO;2-Q) (Pubitemid 26393674)
137. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA & Fagin JA 2008 Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-Related Cancer 15 1069-1074. (doi:10.1677/ERC-08-0036)
138. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA& Fagin JA 2013 Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS ONE 8 e54302. (doi:10.1371/journal.pone.0054302)
139. Sanchez-Capelo A 2005 Dual role for TGF-β1 in apoptosis. Cytokine & Growth Factor Reviews 16 15-34. (doi:10.1016/j.cytogfr.2004.11.002)
140. Sato T, McCue P,Masuoka K, Salwen S, Lattime EC, MastrangeloMJ& Berd D 1996 Interleukin 10 production by human melanoma. Clinical Cancer Research 2 1383-1390. (Pubitemid 26299438)
141. Scarpino S, Stoppacciaro A, Colarossi C, Cancellario F, Marzullo A, Marchesi M, Biffoni M, Comoglio PM, Prat M & Ruco LP 1999 Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. Journal of Pathology 189 570-575. (doi:10.1002/(SICI)1096-9896(199912) 189:4〈570::AID-PATH470〉.0.CO;2-3)
142. Schott M 2006 Immunosurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocrine-Related Cancer 13 779-795. (doi:10.1677/erc.1.01133) (Pubitemid 44763257)
143. Schroder S, Schwarz W, Rehpenning W, Loning T & Bocker W 1988 Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. American Journal of Clinical Pathology 89 295-300. (Pubitemid 18081228)
144. Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E & Dimitrakopoulos G 2013 The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. American Journal of Surgery 205 691-696. (doi:10.1016/j.amjsurg. 2012.08.006)
145. Sipos JA & Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clinical Oncology 22 395-404. (doi:10.1016/j.clon.2010.05. 004)
146. Smyth MJ, Thia KY, Street SE,Cretney E, Trapani JA, TaniguchiM, Kawano T, Pelikan SB, Crowe NY & Godfrey DI 2000 Differential tumor surveillance by natural killer (NK) and NKT cells. Journal of Experimental Medicine 191 661-668. (doi:10.1084/jem.191.4.661)
147. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G & DeMaria R 2003 Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Research 63 6784-6790. (Pubitemid 37322959)
148. Steinman RM 1991 The dendritic cell system and its role in immunogenicity. Annual Review of Immunology 9 271-296. (doi:10.1146/annurev.iy. 09.040191.001415)
149. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ & Lazar MA 2005 Activation of SOCS-3 by resistin. Molecular and Cellular Biology 25 1569-1575. (doi:10.1128/MCB.25.4.1569-1575.2005) (Pubitemid 40204931)
150. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF & Peng G 2010 Tumor microenvironments direct the recruitment and expansion of human Th17 cells. Journal of Immunology 184 1630-1641. (doi:10.4049/jimmunol.0902813)
151. Sun CA, Wu MH, Chu CH, Chou YC, Hsu GC, Yang T, Chou WY, Yu CP & Yu JC 2010 Adipocytokine resistin and breast cancer risk. Breast Cancer Research and Treatment 123 869-876. (doi:10.1007/s10549-010-0792-4)
152. Suzuki S, Mita S, Kamohara H, Sakamoto K, Ishiko T & Ogawa M 2001 IL-6 and IFN-g regulation of IL-10 production by human colon carcinoma cells. International Journal of Oncology 18 581-586.
153. Suzuki K, Kachala SS, Kadota K, Shen R,MoQ, BeerDG, RuschVW, TravisWD & Adusumilli PS 2011 Prognostic immune markers in non-small cell lung cancer. Clinical Cancer Research 17 5247-5256. (doi:10.1158/1078-0432.CCR-10- 2805)
154. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S & Walsh K 2007 Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. Journal of Clinical Investigation 117 375-386. (doi:10.1172/JCI29709) (Pubitemid 46203966)
155. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V & Topuz E 2005 The value of serum levels of IL-6, TNF-α, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Medical Oncology 22 241-246. (doi:10.1385/MO:22:3:241) (Pubitemid 41176320)
156. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H et al. 2006 Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Research 66 3381-3385. (doi:10.1158/0008-5472.CAN-05-4303)
157. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G et al. 2006 Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Research 66 1491-1499. (doi:10.1158/0008-5472.CAN-05-2514) (Pubitemid 43259930)
158. Ugolini C, Basolo F, Proietti A, Vitti P, Elisei R, Miccoli P & Toniolo A 2007 Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 17 389-393. (doi:10.1089/thy.2006.0306) (Pubitemid 46878841)
159. Vella V, Mineo R, Frasca F, Mazzon E, Pandini G, Vigneri R & Belfiore A 2004 Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. Journal of Clinical Endocrinology and Metabolism 89 2880-2889. (doi:10.1210/jc.2003-031639) (Pubitemid 38766380)
160. Vendramini-Costa DB & Carvalho JE 2012 Molecular link mechanisms between inflammation and cancer. Current Pharmaceutical Design 18 3831-3852. (doi:10.2174/138161212802083707)
161. Villagelin DG, Santos RB & Romaldini JH 2011 Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis? Journal of Endocrinological Investigation 34 e403-e408.
162. de Visser KE, Eichten A & Coussens LM 2006 Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer 6 24-37. (doi:10.1038/nrc1782) (Pubitemid 43053650)
163. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM & Ugolini S 2011 Innate or adaptive immunity? The example of natural killer cells Science 331 44-49. (doi:10.1126/science.1198687)
164. Wajant H 2009 The role of TNF in cancer. Results and Problems in Cell Differentiation 49 1-15.
165. Waldmann TA 2006 The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Reviews. Immunology 6 595-601. (doi:10.1038/nri1901) (Pubitemid 44134092)
166. Walsh SR, Cook EJ, Goulder F, Justin TA & Keeling NJ 2005 Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of Surgical Oncology 91 181-184. (doi:10.1002/jso.20329) (Pubitemid 41254421)
167. Wartofsky L 2010 Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones 9 103-108.
168. Xu L, Morari EC, Wei Q, Sturgis EM & Ward LS 2012 Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 1913-1921. (doi:10.1210/jc.2011-3299)
169. Yadav NS, Singh P, Bansode FW & Singh RK 2012 Role of cytokine signalling in head and neck cancers. International Journal of Basic and Applied Medical Sciences 2 6.
170. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K & Ito K 2007 Recent outcome of Graves' disease patients with papillary thyroid cancer. European Journal of Endocrinology 157 325-329. (doi:10.1530/EJE-07-0136) (Pubitemid 47603537)
171. Yokota T,Oritani K, Takahashi I, Ishikawa J,Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y et al. 2000 Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth ofmyelomonocytic progenitors and the functions of macrophages. Blood 96 1723-1732. (Pubitemid 30661055)
172. Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q & Yu J 2013 Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 44 172-181. (doi:10.1007/s12020-012-9853-2)
173. Yuasa R, Eggo MC, Meinkoth J, Dillmann WH & Burrow GN 1992 Iodide induces transforming growth factor b1 (TGF-β1) mRNA in sheep thyroid cells. Thyroid 2 141-145. (doi:10.1089/thy.1992.2.141)
174. Zahorec R 2001 Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratislavské Lekárske Listy 102 5-14.
175. Zanetti A, Stoppacciaro A, Marzullo A, Ciabatta M, Fazioli F, Prat M, Comoglio PM, Baroni CD & Ruco LP 1998 Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. Journal of Pathology 186 287-291. (doi:10.1002/(SICI)1096- 9896(199811)186:3〈287::AID-PATH175〉3.0.CO;2-X) (Pubitemid 28494357)
176. Zhang YJ, Zhao W, Zhu MY, Tang SS & Zhang H 2013 Thyroid-stimulating hormone induces the secretion of tumor necrosis factor-a from 3T3-L1 adipocytes via a protein kinase A-dependent Pathway. Experimental and Clinical Endocrinology & Diabetes 121 488-493.
177. Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J & Cao HY 2012 Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. Journal of International Medical Research 40 2041-2050. (doi:10.1177/ 030006051204000601)
178. Zhou G & Levitsky HI 2007 Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. Journal of Immunology 178 2155-2162. (Pubitemid 46233413)